← All trials
NCT05007951
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 30, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- Sep 30, 2022
- First posted
- Aug 17, 2021
- Last posted
- Oct 22, 2021
- Enrollment
- 3990
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- SK Bioscience Co., Ltd.Lead sponsor
- Korea UniversityOverall official - principal investigator
- GlaxoSmithKlineCollaborator
- International Vaccine InstituteCollaborator
- Coalition for Epidemic Preparedness InnovationsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.